Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2023-05-26 Call Transcript
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for the quarter and year ended March 31, 2023, for Indoco Remedies Limited. It includes management commentary, financial results, business highlights, and Q&A with analysts. The text explicitly states it is a transcript of the earnings conference call, which is a full text transcript of a company conference call discussing quarterly and annual financial results. Therefore, the document fits the definition of a Call Transcript (CT).
2023-05-26 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Postal Ballot Notice dated May 23, 2023, issued by Indoco Remedies Limited. It is addressed to stock exchanges and shareholders, seeking approval for the re-appointment of a director and approval for advancing loans/guarantees under the Companies Act, 2013. The document references regulatory compliance under SEBI Listing Regulations and MCA Circulars. It details the voting process via e-voting and the timeline for voting and announcement of results. The document is a notice to shareholders to vote on specific resolutions and does not contain financial statements or results. It is not a report but a solicitation for shareholder approval via postal ballot. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings or resolutions.
2023-05-26 English
Copy of Newspaper Publication
Regulatory Filings
2023-05-24 English
Code of Conduct under SEBI(PIT) Reg., 2015
Regulatory Filings Classification · 95% confidence The document is a detailed 'Code of Conduct for Prevention of Insider Trading and Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information' issued by Indoco Remedies Limited. It references compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and includes definitions, policies, and procedures related to insider trading prevention and fair disclosure. It is not a financial report, earnings release, or announcement of voting results. It is a regulatory compliance document detailing internal policies and procedures related to governance and regulatory adherence. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2023-05-23 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a disclosure of related party transactions for the half-year ended 31st March 2023, submitted to stock exchanges as per SEBI Listing Regulations. It contains detailed financial data on transactions with related parties, including managerial remuneration, loans, and payments. The document is not a full financial report like an Annual or Interim Report but a regulatory disclosure specific to related party transactions. It is not an announcement of a report but the actual disclosure itself, with substantive financial data. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-05-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the availability of the audio recording of the earnings conference call for the quarter and year ended March 31, 2023. It references the SEBI Listing Regulations and provides a link to the audio recording on the company's website. The document does not contain the transcript itself but announces the availability of the call recording. Given the short length (1324 characters) and the nature of the content (announcement of the call recording), this fits the category of a Regulatory Filing (RNS) rather than a full Call Transcript (CT) or Earnings Release (ER).
2023-05-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.